Swedbank AB Has $24.44 Million Position in Insulet Corporation $PODD

Swedbank AB raised its stake in shares of Insulet Corporation (NASDAQ:PODD) by 11.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 85,988 shares of the medical instruments supplier’s stock after buying an additional 8,500 shares during the quarter. Swedbank AB owned about 0.12% of Insulet worth $24,441,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Larson Financial Group LLC lifted its holdings in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares in the last quarter. Elyxium Wealth LLC bought a new position in shares of Insulet during the 4th quarter valued at about $28,000. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of Insulet by 48.9% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 43 shares in the last quarter. Measured Wealth Private Client Group LLC bought a new position in shares of Insulet during the 3rd quarter valued at about $49,000. Finally, Osterweis Capital Management Inc. bought a new position in shares of Insulet during the 2nd quarter valued at about $51,000.

Insider Activity

In related news, Director Michael R. Minogue acquired 2,030 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were bought at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the purchase, the director directly owned 17,483 shares in the company, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.36% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

PODD has been the topic of several recent analyst reports. Stifel Nicolaus cut their price objective on Insulet from $350.00 to $250.00 in a report on Thursday, May 7th. Jefferies Financial Group cut their price objective on Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. Citigroup cut their price objective on Insulet from $230.00 to $175.00 in a report on Thursday, May 7th. Barclays cut their price objective on Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a report on Thursday, May 7th. Finally, Piper Sandler cut their price objective on Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Twenty-one analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $254.96.

Insulet Stock Performance

NASDAQ PODD opened at $154.87 on Tuesday. The stock has a market capitalization of $10.73 billion, a price-to-earnings ratio of 36.02, a PEG ratio of 1.22 and a beta of 1.20. The stock’s 50 day moving average price is $189.91 and its two-hundred day moving average price is $249.64. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. Insulet Corporation has a 52 week low of $145.59 and a 52 week high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter in the prior year, the business posted $1.02 EPS. The business’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, analysts anticipate that Insulet Corporation will post 6.43 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.